Grifols in a massive sell-off - looking for opportunities
The chart is self-explanatory!
Price to earnings getting very low, company is solid and should see a bounce sooner or later at major support levels.
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
64.13 M USD
7.13 B USD
257.30 M
About GRIFOLS S.A.
Sector
CEO
Nacho Abia
Headquarters
Barcelona
Website
Founded
1940
FIGI
BBG001QMCKF6
Grifols SA engages in the production of plasma derivatives. It operates through the following segments: Bioscience, Hospital, Diagnostic, Bio Supplies, and Others. The Bioscience Segment includes all activities related with products deriving from human plasma for therapeutic use. The Hospital Segment comprises of all non-biological pharmaceutical products and medical supplies manufactured by group companies earmarked for hospital pharmacy. The Diagnostic Segment deals with the marketing of diagnostic testing equipment, reagents, and other equipment. The Bio Supplies segment consists of all transactions related to biological products for non-therapeutic use. The Others segment focuses on the rendering of manufacturing services to third party companies. The company was founded by José Antonio Grifols Roig on November 18, 1940 and is headquartered in Barcelona, Spain.
Buy $GRFS - NRPicks 22 AprGrifols, S.A. is engaged in the acquisition, manufacture, preparation and sale of therapeutic products, mainly plasma derivatives. The company operates through the bioscientific, hospital, diagnostic, biosupplies and other divisions.
Buy $GRFS - NRPicks 11 MarGrifols, S.A. engages in the acquisition, manufacture, preparation and sale of therapeutic products, principally plasma derivatives. The company operates through the Bioscience, Hospital, Diagnostics, Bio Supplies and Others segments.
Revenue TTM 5.6B
Net Income TTM 208M
EBITDA TTM 894M
EBITDA mar
Predicción GRF 28-12-2021Predicción para GRF en Corto. Recomendada por nuestro algoritmo de IA. El horizonte temporal de la recomendación es 5 días.
Are we at the bottom yet?Grifols stock has been heavely punished during 2021.
First the pandemic difficulted the plasma collection. We must take into account the stimulus checks and the unemployment benefits from the US goverment wich might have disuaded people from going to the plasma collection centers to get some extra
GRF is set for actionA nice triangle at the end of a long way down. Even though we did not face the ultimate action, the chances are the stage is set for upside. The best case is to see the short-lived break down but the solo break up is valid as well.
GRIFOLS: Throw-back becoming a reality?After surpassing Fib 0.5, it looks like the stock is heading towards 0.382 level (21.81). Right now the company is immersed in a share repurchase program since 12/03/2021 and it has already acquired 19.23% of its €125 million valued shares objective. Maybe the company's financial advisers are playin
GRIFOLS: Results day coming on Feb 26. Then to the moon?68.2% of GRIFOLS revenues come from the US and Canada. Covid19 cases there seem to be decreasing. The company is delaying more and more its deadline of results for the phase III of the inmunoglobulina antiCovid-19, now until spring 2021.
If GRLS results are positive or better than expected (speciall
See all ideas
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
GRFS5271380
Grifols Escrow Issuer SA 4.75% 15-OCT-2028Yield to maturity
6.73%
Maturity date
Oct 15, 2028
Explore more bonds